The autacoid and neurotransmitter histamine activates the H 1 G protein-coupled receptor (GPCR) to stimulate predominantly phospholipase C (PLC)/inositol phosphate (IP) signaling and, to a lesser extent, adenylyl cyclase (AC)/cAMP signaling in a variety of mammalian cells and tissues, as well as H 1 -transfected clonal cell lines. This study reports that two novel H 1 receptor ligands developed in our laboratory, (Ϫ)-trans-1-phenyl-3-dimethylamino-1,2,3,4-tetrahydronaphthalene (trans-PAT) and (Ϯ)-cis- 5-phenyl-7-dimethylamino-5,6,7,8-tetrahydro-9H- Results suggest the trans-PAT and cis-PAB probes will be useful to study molecular mechanisms of liganddirected GPCR multifunctional signaling. Moreover, because most untoward cardiovascular-, respiratory-, and gastrointestinal H 1 receptor-mediated effects proceed via the PLC/IP pathway, PAT-type agonists that selectively enhance H 1 -mediated AC/cAMP signaling provide a mechanistic basis for exploiting H 1 receptor activation for drug design purposes.
The histamine H 1 protein is a G protein-coupled receptor (GPCR) first cloned and characterized from bovine adrenal gland in 1991 (Yamashita et al., 1991) . The cDNA genes encoding the H 1 receptor from other species were cloned soon after, including for human (De Backer et al., 1993) . Southern blot analysis with H 1 receptor probes indicates that there are no related genes in various species, and there is no compelling evidence for H 1 receptor subtypes (Smit et al., 1999) , although interspecies heterogeneity regarding H 1 pharmacology is known (Seifert et al., 2003) . In most types of mammalian smooth muscle, endothelial, and brain tissue, histamine activation of H 1 receptors triggers G␣ q protein activation with subsequent stimulation of phospholipase C (PLC) and increased intracellular formation of inositol phosphates (IP) and diacylglycerol (Hill et al., 1997) .
In mammalian brain and adrenal gland, activation of H 1 receptors also stimulates adenylyl cyclase (AC) and intracellular formation of cAMP. In rat brain, H 1 -mediated stimulation of cAMP formation is enhanced by protein kinase C activation and is dependent on intra-and extracellular calcium (Garbarg and Schwartz, 1988) . In bovine adrenal cells, H 1 -mediated stimulation of cAMP formation also is dependent on extracellular calcium (Marley et al., 1991) . In H 1 -transfected CHO (CHO-H 1 ) cells, histamine H 1 activation augments forskolin-stimulated cAMP formation by a mecha-nism not sensitive to extracellular calcium, nor protein kinase C activation, and is pertussis toxin-insensitive . Thus, although details such as G protein, kinase, and calcium involvement are not clear, H 1 receptors also can modulate AC/cAMP signaling in addition to PLC/IP signaling. This dual signaling mechanism now is thought to be common among GPCRs.
The phenomenon of multiple signaling pathways associated with a single GPCR can be described within the framework of the three-state model of GPCR activation (Leff et al., 1997) , wherein GPCRs isomerize between inactive and constitutively active states (Kenakin, 2001) . GPCR activation causes dissociation of heterotrimeric (␣,␤,␥) G protein subunits, the G␣ subunit can then activate transducer protein (e.g., PLC and AC) to alter second messenger concentration. In addition to a role for G-␤␥ subunits in signal transduction (Clapham and Neer, 1997) , it also is now realized the same GPCR can couple to different G␣ proteins to result in "multifunctional signaling" (Milligan, 1993) . A critical assumption of the GPCR multifunctional signaling theory is that a heterogeneity of active receptor conformations exists and that agonist ligands differ in their ability to induce, stabilize, or select among receptor conformations, as described in the "stimulus trafficking" hypothesis (Kenakin, 2001) . It follows that, upon binding, agonist ligand chemical structural parameters are among the most important determinants of GPCR conformation that influences type of G␣ protein and signaling pathway activated.
Previously, it was reported that the novel selective histamine H 1 ligand (Ϫ)-trans-1-phenyl-3-dimethylamino-1,2,3,4-tetrahydronaphthalene (trans-PAT; Fig. 1 ) stimulates tyrosine hydroxylase activity and dopamine synthesis in rat and guinea pig forebrain in vitro and in vivo, by activating presynaptic H 1 receptors Choksi et al., 2000) . This effect of trans-PAT is similar to that observed for the endogenous agonist histamine (Fleckenstein et al., 1993) , and effects of both ligands can be blocked specifically by typical H 1 antagonists such as triprolidine (Fig. 1) . Based on these results, trans-PAT was proposed as a putative agonist at H 1 receptors linked to modulation of tyrosine hydroxylase, the rate-limiting enzyme in catecholamine neurotransmitter synthesis (Choksi et al., 2000) . Subsequently, it was reported that trans-PAT also behaves as a potent antagonist (pA 2 ϭ 9.2) regarding H 1 -mediated contraction of guinea pig ileum, and trans-PAT fully blocks H 1 receptor activation of PLC/IP formation in CHO-H 1 cells . Radioreceptor competition binding results, using the standard H 1 antagonist radioligand [ 3 H]mepyramine ( Fig. 1) , show the Hill coefficient (n H ) for the slope of the displacement curve by trans-PAT consistently is ϳ0.9 using membranes prepared from rodent tissues and H 1 -transfected clonal cell lines Choksi et al., 2000) , characteristic of agonist ligand binding at a GPCR, according to the ternary complex model with limiting availability of G protein (De Lean et al., 1980) . The complex H 1 receptor activity shown by trans-PAT also has been observed in pilot studies for another PAT-type derivative, (Ϯ)-cis-5-phenyl-7-dimethylamino-5,6,7,8-tetrahydro-9H-benzocycloheptane (cis-PAB; Fig. 1 ), that behaves as an H 1 agonist or antagonist, depending on the functional assay (Moniri and Booth, 2004) . The preliminary functional results reported for trans-PAT and cis-PAB are reminiscent of activities shown by certain dopamine D 2 receptor ligands that are agonists at postsynaptic D 2L receptors but antagonists at presynaptic D 2L receptors Mottola et al., 2002) . The term "functional selectivity" was used to describe this phenomenon wherein a ligand that acts as an agonist at a GPCR linked to one particular signaling pathway may act as an antagonist at the same receptor linked to another signaling pathway. Functional selectivity can be exploited for drug design purposes as a practical application of the multifunctional signaling and stimulus-trafficking hypotheses.
In this article, we report the unique H 1 binding and selective functional activity (PLC/IP versus AC/cAMP signaling) of cis-PAB and trans-PAT, two novel H 1 ligands that are from the same chemical class but differ primarily with regard to stereochemistry (Fig. 1) . Results of these studies suggest delineation of ligand molecular structural parameters that determine functionally selective binding should be an important consideration involved in designing GPCR-active drugs with predictable and selective pharmacotherapeutic effects versus untoward side effects. (Fig. 1 ) was synthesized as described previously (Wyrick et al., 1993) . Briefly, the benzylstyrylketone was cyclized to the tetralone intermediate and reduced to the (Ϯ)-cis-and (Ϯ)-trans-tetralols. This diastereomeric tetralol mixture was converted to the free amine, followed by dimethylation and fractional recrystallization, to isolate (Ϯ)-trans-PAT. The (Ϯ)-trans-PAT enantiomeric mixture was converted to the (Ϫ)-camphorsulfonic acid diastereomeric salt and resolved by fractional recrystallization to yield the pure (1R,3S)-(Ϫ)-trans-PAT isomer (Wyrick et al., 1993; Bucholtz et al., 1998 Bucholtz et al., , 1999 . To synthesize cis-PAB ( Fig. 1) (Wyrick et al., 1995) , the corresponding diphenylpentenone was cyclized to the tetrahydrobenzocycloheptanone and reduced to the (Ϯ)-cis-and (Ϯ)-trans-tetrahydrobenzocycloheptanol diastereomers, which could be separated using silica gel column chromatography. Conversion of the (Ϯ)-cis-alcohols to the free amine, followed by dimethylation, gave (Ϯ)-cis-PAB as a solid that could be purified as the HCl salt; (Ϯ)-trans-PAB resisted crystallization and remained a gum. Resolution . Clonal transfects expressing the H 1 receptor (CHO-H 1 ) were selected for in ␣-minimal essential media without ribonucleosides and supplemented with 10% fetal bovine serum and 2 mM L-glutamine. For binding and functional studies, CHO-H 1 cells were grown to 90% confluence in 75-cm 2 tissue culture flasks containing ␣-minimum essential medium, supplemented with 10% fetal bovine serum, 2 mM L-glutamine, and 0.1% penicillin-streptomycin (100 units/100 g/ml), in a humidified atmosphere of air, CO 2 (95: 5%) at 37°C.
Materials and Methods

Chemicals. trans-PAT
Null-transfected CHO-K1 cells were cultured as described above and used to verify that effects observed were H 1 receptor-dependent (selective H 1 antagonists also were used). Essentially, no H 1 radioligand specific binding was detected in membranes prepared from CHO-K1 cells as [
3 H]mepyramine total and nonspecific saturation binding was 480 Ϯ 49 and 460 Ϯ 27 fmol/mg protein (mean Ϯ S.E.M.), respectively. Also, essentially no histamine receptor-mediated IP or cAMP second messenger formation was detected in lysates of CHO-K1 cells because second messenger levels were 99 Ϯ 1.3% of basal control values (mean Ϯ S.E.M.) after exposure to 10 M histamine for 15 to 45 min.
Radioreceptor Assays. Radioligand competition and saturation binding assays were performed using membrane homogenate prepared from CHO-H 1 cells, as reported previously . For competition binding assays, membranes were incubated with ϳK D concentration of the standard H 1 antagonist radioligand [ 3 H]mepyramine (1.0 nM) plus test ligand (0.01-10,000 nM). For saturation isotherms, membranes were incubated in 0.01 to 10.0 nM [ 3 H]mepyramine; some conditions included the H 1 antagonist triprolidine, trans-PAT, or cis-PAB, where possible, at ϳK 0.5 , 10 times K 0.5 , or 100 times K 0.5 . concentration. Both assays used 50 mM Na ϩ -K ϩ phosphate buffer (total assay volume was 0.4 ml), incubation was for 30 min at 25°C, and nonspecific binding was defined by triprolidine (10 M). Inhibition data were analyzed by nonlinear regression using the sigmoidal curve-fitting algorithms in Prism 3.0 (GraphPad Software Inc., San Diego, CA) to determine IC 50 and Hill coefficient (n H ). In light of the incompletely characterized nature of the interaction between the H 1 receptor and the novel ligands used here, ligand affinity is expressed as an approximation of K i values by converting IC 50 data to K 0.5 values using the equation
where L is the concentration of radioligand having affinity K D (Cheng and Prusoff, 1973) . Each experimental condition was run in triplicate and each experiment was performed a minimum of three times to determine S.E.M.
Measurement of [ 3 H]Inositol Phosphate Formation in CHO-H 1 Cells. Formation of [
3 H]IP was measured in CHO-H 1 cells, as described previously ). Briefly, CHO-H 1 cells were incubated overnight in 12-well culture plates (ϳ7.0 ϫ 10 expressed as mean percentage of control [ 3 H]IP formation, and potencies are expressed as concentrations required to produce 50% maximal
. Measurement of cAMP Formation in CHO-H 1 Cells. Formation of cAMP was measured in CHO-H 1 cells grown in 24-well plates, preincubated for 5 min in serum-free media in the presence of the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (1.0 mM), followed by addition of drug stocks in serum-free media. After incubation for 15 min at 37°C, plates were placed on ice, and the cells were lysed by addition of 0.1 M HCl followed by sonication. Well contents were centrifuged (700g; 10 min) individually, and aliquots of the supernatants were used in the direct-cAMP immunoassay kit (Assay Designs Inc., Ann Arbor, MI). Data were expressed as mean percentage of control cAMP formation as obtained by linear standard curve extrapolation, and potencies are expressed as concentrations required to produce 50% maximal cAMP formation (EC 50 ) Ϯ S.E.M. (n Ն 3).
Results
H 1 Radioreceptor Binding Assays Using CHO-H 1 Cell Membranes
Competition Binding Analysis. Representative H 1 radioligand (the antagonist [ 3 H]mepyramine) displacement curves for trans-PAT and cis-PAB, in comparison with the endogenous agonist histamine and the standard competitive H 1 antagonist triprolidine (Hill et al., 1997) , are shown in Fig. 2 . Curves are sigmoidal and span three to four log ligand concentration units to achieve complete radioligand displacement, characteristic of competitive displacement of ϳK D radioligand concentration from a single population of GPCRs. Values for K 0.5 Ϯ S.E.M. (nanomolar) for triprolidine, trans-PAT, cis-PAB, and histamine are 0.93 Ϯ 0.16, 1.15 Ϯ 0.36, 175.0 Ϯ 16.0, and 18,300 Ϯ 1200, respectively. n H for the slope of the competitive displacement curve was ϳ1.0 (0.98 Ϯ 0.08) for the H 1 antagonist triprolidine. n H was Ͻ 1.0 for trans-PAT, cis-PAB, and histamine (n H Ϯ S.E.M.; 0.87 Ϯ 0.14, 0.77 Ϯ 0.03, and 0.72 Ϯ 0.09, respectively), characteristic of agonist ligand binding at a GPCR, according to the ternary complex model with limiting availability of G protein (De Lean et al., 1980) . Saturation Binding Analysis. Figure 3 , A to C, shows representative saturation binding curves for [
3 H]mepyramine alone and in the presence of triprolidine, cis-PAB, and trans-PAT, at increasing concentration (ϳK 0.5 , ϳ10 times K 0.5 and ϳ100 times K 0.5 , except for cis-PAB, where maxi- Figure 3B shows that analogous results are obtained using cis-PAB as displacing ligand, i.e., there is no significant change in [ 3 H]mepyramine B max , but K D value increases from 0.43 Ϯ 0.02 nM in absence of cis-PAB to 0.52 Ϯ 0.01, 2.50 Ϯ 0.03, and 7.31 Ϯ 0.31 nM in the presence of 0.1, 0.5, and 1.0 M cis-PAB, respectively (ANOVA; p Ͻ 0.0001). Thus, it seems cis-PAB binding to H 1 receptors also is according to typical competitive kinetics. In contrast, Fig. 3C shows that when the displacing ligand is trans-PAT, the [ 3 H]mepyramine B max value decreases from 260 Ϯ 4.9 fmol/mg protein in absence of trans-PAT to 230 Ϯ 1.1, 160 Ϯ 4.4, and 52 Ϯ 0.6 fmol/mg protein in presence of 1.0, 10, and 100 nM trans-PAT, respectively (ANOVA; p Ͻ 0.0001). Also, Fig. 3C Figure 4 shows that histamine stimulates PLC/[ 3 H]IP formation in a concentration-dependent manner in CHO-H 1 cells, with E max of ϳ100 M (ϳ900% basal control activity) and EC 50 of ϳ3 M; the effect at EC 50 is fully blocked by the competitive H 1 antagonist triprolidine (Fig. 4, inset) . Also shown in Fig. 4 , cis-PAB stimulates formation of [ 3 H]IP in CHO-H 1 cells in a concentration-dependent manner. Although solubility problems limited maximal cis-PAB concentrations to ϳ30 M, it could be determined that E max is ϳ10 M (ϳ200% basal control activity; ϳ20% histamine E max ) and EC 50 is ϳ140 nM; the effect at EC 50 is fully blocked by triprolidine (Fig. 4, inset) . Even at concentrations up to 30 M, trans-PAT had no effect to stimulate [ 3 H]IP formation in CHO-H 1 cells (Fig. 4) .
Stimulation of PLC/IP Formation in CHO-H 1 Cells
Although cis-PAB is ϳ20-fold more potent than histamine at stimulating [ 3 H]IP formation (EC 50 ϳ140 nM versus 3.0 M), the maximal stimulation produced by cis-PAB is ϳ20% of the histamine maximal response. These results suggest that in comparison with the endogenous agonist histamine, cis-PAB is a partial agonist regarding H 1 -mediated stimulation of PLC/IP formation; accordingly, cis-PAB should seem to be an antagonist in the presence of histamine in this H 1 functional assay. Figure 5 shows that, in fact, histamine H 1 -mediated stimulation of PLC/[
3 H]IP formation is competitively antagonized by cis-PAB, as indicated by a histamine EC 50 value that increases as concentration of cis-PAB increases (shift to the right in concentration-response curve), i.e., histamine EC 50 is ϳ3 M in absence of cis-PAB, but histamine EC 50 increases to ϳ8 and ϳ25 M in presence of 0.1 and 1.0 M cis-PAB, respectively (ANOVA; p Ͻ 0.0001). Histamine E max for stimulation of PLC/IP formation is achieved, regardless of the concentration of cis-PAB present. As described by Kenakin (1993) , competitive antagonism by a weak partial agonist (i.e., cis-PAB) can be treated as competitive agonism by the antagonist, because the error in the apparent K B value introduced by the weak partial agonist is negligible. Assuming competitive antagonism by cis-PAB, the data in Fig. 5 yield an apparent K B value of 180 nM.
The Fig. 5 inset shows that, as expected, the H 1 antagonist triprolidine also competitively antagonizes histamine stimulation of [ 3 H]IP formation. This result is indicated by histamine EC 50 values that increase concomitant with increasing concentration of triprolidine, i.e., the histamine EC 50 is ϳ4 M in absence of triprolidine, but increases to ϳ40 and ϳ300 M in presence of 0.01 and 0.01 M triprolidine, respectively (ANOVA; p Ͻ 0.0001). For triprolidine, the data in Fig. 5 yield an apparent K B value of 2.0 nM (nearly 100 times more potent than cis-PAB, consistent with its higher H 1 affinity). Overall, the results in Figs. 4 and 5 confirm the H 1 competitive antagonist activity of triprolidine and identify cis-PAB as a novel potent partial agonist (in comparison with histamine) at H 1 receptors that activate PLC/IP formation.
Results summarized in Fig. 6 show that in contrast to the competitive antagonism observed for cis-PAB and triprolidine (Fig. 5) , trans-PAT antagonism of histamine H 1 -mediated stimulation of PLC/[ 3 H]IP formation apparently is not competitive. For instance, the histamine EC 50 is ϳ3 M in the absence of trans-PAT, but the EC 50 value increases to ϳ10, 17, and 27 M in presence of 0.01, 0.1, and 1.0 M trans-PAT, respectively (ANOVA; p Ͻ 0.0001). Also, the histamine E max decreases from 100% response in the absence of trans-PAT to ϳ 95, 60, and 50% response in presence of increasing concentrations of trans-PAT (ANOVA; p Ͻ 0.0001). As shown in the Fig. 6 inset, trans-PAT antagonism of cis-PAB H 1 -mediated stimulation of PLC/[ 3 H]IP formation seems to be competitive. For instance, whereas the cis-PAB EC 50 is ϳ85 nM in the absence of trans-PAT, the EC 50 value increases to ϳ850 and 2600 nM in the presence of 0.01 and 0.1 M trans-PAT, respectively (ANOVA; p Ͻ 0.0001). Also, consistent with competitive antagonism, the cis-PAB E max is unchanged in the absence or presence of trans-PAT (ANOVA; p ϭ 0.2). 
Stimulation of AC/cAMP Formation in CHO-H 1 Cells
Results in Fig. 7 show that histamine stimulates AC/cAMP formation over basal control levels in a concentration-dependent manner in CHO-H 1 cells, with E max ϳ100 M (ϳ170% basal control activity) and EC 50 ϳ2.1 M. Moreover, the novel H 1 ligand trans-PAT also stimulates AC/cAMP in this assay system with efficacy and potency similar to histamine. Although solubility problems limited maximal trans-PAT concentrations to ϳ1.0 mM, it could be determined that E max is ϳ160% basal level at 100 M and EC 50 is ϳ2.0 M. Maximal response for both histamine and trans-PAT is comparable with the AC activator forskolin (ϳ173% basal at 1.0 M) here, and the histamine response also is comparable with that observed in bovine adrenal cells (ϳ200%) (Marley et al., 1991) . At EC 50 , both histamine and trans-PAT H 1 -mediated increases in cAMP are significantly different than basal (p Ͻ 0.01), and effects of both ligands are fully blocked by the H 1 antagonist triprolidine (data not shown). At concentrations 0.01 to 100 M, cis-PAB alone had no effect on cAMP formation, but it could competitively antagonize H 1 -mediated stimulation of AC/cAMP formation produced by trans-PAT (Fig. 7, inset ) and histamine (data not shown).
Discussion
Results of these studies indicate that the novel H 1 ligands trans-PAT and cis-PAB can display mutually opposing activity and selectively activate and block different H 1 -linked intracellular signaling pathways, i.e., the AC/cAMP and PLC/IP signaling cascades. The endogenous agonist histamine, on the other hand, nonselectively activates both H 1 pathways. The literature now documents many observations of the same GPCR activating different intracellular signaling pathways. For example, adrenergic ␣ 1B receptors, which predominantly couple to G␣ q /PLC to stimulate IP formation, also can couple to G␣ S /AC to stimulate cAMP formation in CHO cells expressing ␣ 1B cDNA (Horie et al., 1995) . The reverse also is observed, e.g., histamine H 2 receptors, which predominantly couple to G␣ S /AC/cAMP, also can couple to G␣ q /PLC/IP in COS cells expressing H 2 cDNA (Kuhn et al., 1996) . The 5-HT 2C receptor, that is phylogenetically closely related to H 1 receptors (Smit et al., 1999) , predominantly couples to G␣ q to activate PLC but also can modulate AC/ cAMP formation through G␣ i (Cussac et al., 2002) . Recent evidence also suggests that H 1 receptors may mediate antinociception via G i/o signaling in vivo (Galeotti et al., 2002) . GPCRs are not limited to just two different G protein partners; many of the 30 or so different 5-HT receptors couple with several different G proteins and can modulate a halfdozen different intracellular signaling pathways (Raymond et al., 2001) .
Examples of GPCR signaling promiscuity have been demonstrated using native intact cells, primary cultures, and in vivo animal models (Allgeier et al., 1994; Arey et al., 1997; Galeotti et al., 2002) , suggesting that multifunctional signaling among GPCRs is not necessarily an artifact of receptor overexpression in clonal cell lines. On the other hand, receptor and/or G protein overexpression might reveal both qualitative and quantitative ligand-GPCR responses that might not be detected in native cell and tissue preparations. Nevertheless, whereas the H 1 -linked AC/cAMP signaling revealed here for trans-PAT may be due, in part, to receptor and/or G protein overexpression, the lack of effect for cis-PAB to activate H 1 /AC/cAMP signaling in comparison with trans-PAT and histamine in the same assay system indicates that the effect is ligand-specific. Clearly, too, the activity of trans-PAT as a functionally selective full agonist regarding H 1 /AC/ cAMP signaling is a concentration-dependent phenomenon. Thus, whereas trans-PAT binds to the H 1 receptor (Fig. 2) and blocks H 1 /PLC/IP signaling (Fig. 3C ) at concentrations as low as ϳ1.0 nM, significant activation of H 1 /AC/cAMP signaling does not occur until concentration of trans-PAT approaches ϳ1.0 M (Fig. 7) . Whereas the physiological relevance of concentration-dependent functional selectivity is presently unclear, preliminary results presented in this article suggest that specific ligands can be designed to selectively activate or block specific intracellular signaling pathways for multifunctional signaling GPCRs.
Molecular mechanisms to account for GPCR multifunctional signaling involve the concept of "GPCR permissiveness" that assumes a high degree of flexibility in the interactions between a ligand, receptor, and G protein (Raymond, 1995) . These interactions occur mainly between the G proteins and the second and third intracellular loops and carboxy-terminal tail of the receptor. Some factors that influence this interaction include receptor-G protein ratios and amounts, alternative GPCR splicing, and conformational changes in the G protein and/or receptor. In the present study, amount and ratio of H 1 receptors and G protein types expressed in the CHO-H 1 cells probably is a factor in signaling. This is suggested by the robust potency and efficacy of histamine to stimulate H 1 -mediated PLC/IP formation (Fig.  3) such that EC 50 (ϳ2.6 M) is well below K 0.5 (ϳ18 M), and the maximal effect is nearly a 10-fold increase over basal IP formation. In contrast, a 3-fold increase in basal IP formation by histamine is the maximum we found reported using mam- jpet.aspetjournals.org malian brain, adrenal, retina, and ileum tissue preparations (Hill et al., 1997) . Receptor splice variants are not likely to play a role in the ligand-directed signaling results observed here because the CHO-H 1 cells were transfected with H 1 cDNA, and, in any event, we could find no evidence in the literature for the existence of H 1 splice variants. Receptor conformational changes, however, likely are a factor for the current results, given that ligand chemical structure is among the most important molecular determinants for GPCR conformation that leads to activation of signaling (Kenakin, 2001) . Furthermore, there is the phenomenon of spontaneous "precoupling of receptor-G␣ protein complexes" (Leff et al., 1997) that explains observed GPCR constitutive activity, now well documented, including for H 1 receptors (Bakker et al., 2000) . Such spontaneous receptor-G␣ protein coupling suggests that ligand binding influences stabilization of fluctuating GPCR-G␣ conformations and that ligand chemical structural parameters determine which conformation will be stabilized, induced, or selected (Kenakin, 2001) .
The molecular determinants for trans-PAT versus cis-PAB differential binding to the H 1 active site that leads to differential activation of the AC/cAMP versus PLC/IP signaling pathways likely are due, in large part, to stereochemical factors. The H 1 receptor is known to be highly sensitive to the stereochemistry of PAT/PAB-type ligands. For example, cis-PAT is an H 1 antagonist that blocks H 1 -medited stimulation of tyrosine hydroxylase and dopamine synthesis by trans-PAT in rat forebrain (Choksi et al., 2000) . Likewise, rank order of PAT isomer H 1 affinity depends on stereochemistry
-cis) and varies ϳ50-fold (K 0.5 ϳ1-50 nM), with S-chirality at the C3 amine position (Fig. 1) being the most important structural determinate for binding (Buchlotz et al., 1998 (Buchlotz et al., , 1999 . Interestingly, only the (Ϫ)-trans-PAT isomer has H 1 agonist activity (AC activation); the other isomers are H 1 antagonists regarding PLC and AC activation Moniri and Booth, 2004) . Previous molecular modeling studies suggest that the protonated amine moiety of PAT/PAB-type compounds forms an ionic bond with the H 1 Asp 116 residue (guinea pig numbering) in transmembrane helix (TMH) 3. The equivalent TMH3 Asp 116 residue is highly conserved among biogenic amine neurotransmitter GPCRs, and mutagenesis studies suggest this residue interacts with a positively charged amine moiety of endogenous agonists and other ligands (Savarese and Fraser, 1992) , including for the H 1 receptor (Ohta et al., 1994) and the serotonin 5-HT 2 receptor family (Wang et al., 1993; Kristiansen et al., 1996) that is phylogenetically closely related to H 1 (Smit et al., 1999) . Whereas the main structural difference between trans-PAT and cis-PAB is stereochemical, there also is added conformational flexibility in the hexane (PAT) versus heptane (PAB) ring systems, and molecular modeling studies indicate both structural parameters influence orientation of the dimethylamino and appended phenyl moieties . Thus, in addition to differential interactions of the trans-PAT and cis-PAB amine moieties with H 1 TMH 3 residue(s), the phenyl moieties of these ligands may form differential -electron binding interactions with aromatic amino acids of the H 1 receptor binding pocket. In this regard, mutational analysis and molecular dynamics simulations of the H 1 receptor (Elz et al., 2000) and the related 5-HT 2A serotonin receptor (Kroeze et al., 2002) suggest that -stacking interactions occur between bound aromatic-containing ligands and aromatic amino acid residues in TMH 5 and 6. Mutagenesis studies to probe the molecular interactions of trans-PAT versus cis-PAB with H 1 active site amino acid residues currently are underway in our laboratory.
Presently, we have not succeeded in separating the (5R,7S) and (5S,7R) enantiomers of (Ϯ)-cis-PAB. We note that the nearly 5-fold lower efficacy of cis-PAB in comparison to histamine with regard to H 1 -mediated activation of PLC/IP formation (Fig. 5 ) might involve antagonism of one cis-PAB enantiomer by the other, analogous to (ϩ)-trans-PAT antagonism of (Ϫ)-trans-PAT regarding H 1 -mediated activation of tyrosine hydroxylase and dopamine synthesis Choksi et al., 2000) . Based on studies with PAT, we predict that (5S,7R)-cis-PAB will be the more active enantiomer at H 1 receptors because this isomer has the critical dimethylamino moiety in the same configuration as (1R,3S)-(Ϫ)-trans-PAT (stereochemical nomenclature rules result in differential R,S designation for the amine moieties of the two molecules even though they share the same three-dimensional configuration; Fig. 1 ).
The binding interaction between trans-PAT and the H 1 receptor seems to be complex given that it is not competitive with respect to antagonism of H 1 saturation binding by [ 3 H]mepyramine (Fig. 3C ) and H 1 /PLC/IP functional activation by histamine (Fig. 6) . The H 1 /PLC/IP functional interaction between trans-PAT and cis-PAB is typically competitive (Fig. 6, inset) , suggesting that there is overlap in the H 1 binding pharmacophores of trans-PAT and cis-PAB. Here again, mutagenesis studies will be helpful to sort H 1 receptor molecular recognition determinants for trans-PAT versus cis-PAB functionally selective binding that presumably leads to differential activation of AC/cAMP versus PLC/IP signaling.
To the best of our knowledge, the present results are the first to show that different but structurally related ligands can be developed to selectively activate or block two different intracellular signaling pathways for the same GPCR, i.e., H 1 receptors linked to AC/cAMP and PLC/IP signaling. Previously, it has been shown that a novel ligand ([Gly Arg 19 ]hPTH-[1-28]) could be designed to selectively activate one of the two signaling pathways (AC/cAMP versus PLC/IP) associated with the type 1 parathyroid GPCR (Takasu et al., 1999) . The PAT/PAB-type probes, however, will be uniquely useful to study molecular determinants of switching mechanisms involved in GPCR multifunctional signaling. Such functionally selective ligands targeted to GPCRs also hold promising pharmacotherapeutic utility. For example, activation of H 1 -linked PLC/IP signaling in peripheral smooth muscle and endothelial tissues can present clinically as respiratory distress (bronchial constriction), diarrhea (gastrointestinal contractions), and edema and hypotension (increased vascular permeability), especially associated with an allergic response. trans-PAT, however, is a lipophilic molecule that can penetrate brain tissue to selectively activate H 1 -linked AC/cAMP signaling, presumably leading to modulation of tyrosine hydroxylase activity and catecholamine neurotransmitter synthesis (Choksi et al., 2000; Moniri and Booth, 2004) . Because most untoward cardiovascular-, respiratory-, and gastrointestinal H 1 -mediated effects proceed via the PLC/IP pathway (Hill et al., 1997) , PAT-type drugs that selectively enhance H 1 -mediated AC/cAMP signaling in brain provide a mechanistic basis for exploiting H 1 receptors as pharmacotherapeutic targets in 
